EGFR and lung adenocarcinoma: Indeed, a retrospective study in patients with lung adenocarcinoma and bone metastases (n = 410) reported a preventive effect of EGFR-TKIs on the development of SREs: 23.5% of the patients with lung adenocarcinoma who were treated with EGFR-TKIs experienced SREs compared with 61.7% of patients without EGFR-TKI treatment (information about specific treatment in this group is not provided) (p < 0.001) [54].